Skip to content
Original
mp.weixin.qq.com·· 21 hours agoScore93

ESMO 2026 Abstract: CLARITY-Gastric01 Shows Sone-Ve Cuts Death Risk 42% in Second-Line and Later CLDN18.2-Positive Advanced Gastric and GEJ Cancer

In brief

An interim analysis of CLARITY-Gastric01 showed that Sone-Ve reduced the risk of death by 42% in patients with CLDN18.2-positive advanced gastric or gastroesophageal junction cancer in the second-line and later setting. The results were presented in an ESMO 2026 abstract.

Source: mp.weixin.qq.com · mp.weixin.qq.com

#Conference#Oncology#ADCs & conjugates#AstraZeneca
CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org

Disclaimer CBA Frontier Insights uses AI-assisted methods to aggregate, summarize, and analyze publicly accessible biopharmaceutical information. Content is provided for informational and educational purposes only and does not represent the official views of original sources or affiliated organizations. AI-generated content may contain errors; please verify important information against primary sources. Intellectual property rights remain with their respective owners. For copyright concerns or corrections, please contact us through the website’s feedback page.